Eleni Douni Research Group

Rinotas V, Gkikopoulou E, Tzortzis E, Kritikos K, Siatra P, Papadopoulos A, Perivolidi VI, Douni E. 2024, "Interplay between bone marrow adiposity and bone resorption in RANKL-mediated modelled osteoporosis. ", Journal of Cellular Physiology, e31434. doi: 10.1002/jcp.31434 [Link].

Vlasiou MC, Zacharia LC, Douni E, Papaneophytou C. 2024, "Editorial: Targeting mitochondrial dysfunction for the diagnosis and treatment of Alzheimer's and cognitive-related diseases.", Frontiers in Pharmacology, 15:1455646. doi: 10.3389/fphar.2024.1455646. [Link].

Foessl I, Ackert-Bicknell CL, Kague E, Laskou F, Jakob F, Karasik D, Obermayer-Pietsch B; Co-authors; Alonso N, Bjørnerem Å, Brandi ML, Busse B, Calado Â, Cebi AH, Christou M, Curran KM, Hald JD, Semeraro MD, Douni E, Duncan EL, Duran I, Formosa MM, Gabet Y, Ghatan S, Gkitakou A, Hassler EM, Högler W, Heino TJ, Hendrickx G, Khashayar P, Kiel DP, Koromani F, Langdahl B, Lopes P, Mäkitie O, Maurizi A, Medina-Gomez C, Ntzani E, Ohlsson C, Prijatelj V, Rabionet R, Reppe S, Rivadeneira F, Roshchupkin G, Sharma N, Søe K, Styrkarsdottir U, Szulc P, Teti A, Tobias J, Valjevac A, van de Peppel J, van der Eerden B, van Rietbergen B, Zekic T, Zillikens MC. 2024, "A perspective on muscle phenotyping in musculoskeletal research.", Trends in Endocrinoly and Metabolism, 35(6): 478-489. doi: 10.1016/j.tem.2024.01.004. [Link].

Kolokotroni A, Gkikopoulou E, Rinotas V, Ntari L, Zareifi D, Rouchota M, Sarpaki S, Lymperopoulos I, Alexopoulos LG, Loudos G, Denis MC, Karagianni N, Douni E. 2023, "Α Humanized RANKL Transgenic Mouse Model of Progestin-Induced Mammary Carcinogenesis for Evaluation of Novel Therapeutics.", Cancers, 15(15):4006. doi: 10.3390/cancers15154006 [Link].

Rinotas V, Liepouri F, Ouzouni MD, Chalkidi N, Papaneophytou C, Lampropoulou M, Vidali VP, Kontopidis G, Couladouros E, Eliopoulos E, Papakyriakou A, Douni E. 2023, "Structure-Based Discovery of Receptor Activator of Nuclear Factor-κB Ligand (RANKL)-Induced Osteoclastogenesis Inhibitors.", International Journal of Molecular Sciences, 24(14):11290. doi: 10.3390/ijms241411290. [Link].

Kupreienko O, Pouliou F, Konstandinidis K, Axarli I, Douni E, Papageorgiou AC, Labrou NE. 2024, "Inhibition Analysis and High-Resolution Crystal Structure of Mus musculus Glutathione Transferase P1-1.", Biomolecules, 13(4):613. doi: 10.3390/biom13040613 [Link].

Athanasoulia IG, Louli V, Schinas P, Rinotas V, Douni E, Tarantili P, Magoulas K. 2022, "The effect of foaming process with supercritical CO2 on the morphology and properties of 3D porous polylactic acid scaffolds.", Polymer Engineering and Science, 62(8):2459–2475. doi:10.1002/pen.26020. [Link].

Kolokotroni A, Gkikopoulou E, Rinotas V, Douni E. 2023, "Phosphotungstic acid-enhanced microcomputed tomography for quantitative visualization of mouse mammary gland morphology.", Journal of Medical Imaging, 10 (Suppl 2): S22402. doi: 10.1117/1.JMI.10.S2.S22402 [PubMed].

Perivolidi VI, Violitzi F, Ioannidou E, Rinotas V, Stamatakis G, Samiotaki M, Panayotou G, Douni E. (2022). Proteomic Identification of the SLC25A46 Interactome in Transgenic Mice Expressing SLC25A46-FLAG. Journal of Proteome Research; 21(2):375-394. doi: 10.1021/acs.jproteome.1c00728. [PubMed]

Filippopoulou F, Habeos GI, Rinotas V, Sophocleous A, Sykiotis GP, Douni E, Chartoumpekis DV. (2021). Dexamethasone administration in mice leads to less body weight gain over time, lower serum glucose, and higher insulin levels independently of NRF2. Antioxidants; 11(1):4. doi.org/10.3390/antiox11010004 [PubMed]

Foessl I, Duncan Bassett JH, Bjornerem A, Busse B, Calado A, Chavassieux P, Christou M, Douni E, Fiedler IAK, Fonseca JE, Hassler E, Hοgler W, Kague E, Karasik D, Khashayar P, Langdahl BL, Leitch VD, Lopes P, Markozannes G, McGuigan FEA, Medina-Gomez C, Ntzani E, Oei L, Ohlsson C, Szulc P, Tobias JH, Trajanoska K, Tuzun S, Valjevac A, van Rietbergen B, Williams GR, Zekic T, Rivadeneira F, Obermayer-Pietsch B. (2021). Bone Phenotyping Approaches in Human, Mice and Zebrafish – Expert Overview of the EU Cost Action GEMSTONE (“GEnomics of MusculoSkeletal traits TranslatiOnal NEtwork”). Frontiers in Endocrinology; 12:720728. doi: 10.3389/fendo.2021.720728. [PubMed]

Rauner M, Foessl I, Formosa MM, Kague E, Prijatelj V, Lopez NA, Banerjee B, Bergen D, Busse B, Calado A, Douni E, Gabet Y, Garcia-Giralt N, Grinberg D, Lovsin NM, Nogues-Solan X, Ostanek B, Pavlos NJ, Rivadeneira F, Soldatovic I, van de Peppel J, van der Eerden B, van Hul W, Balcells S, Marc J, Reppe S, Soe K, Karasik D. (2021). Perspective of the GEMSTONE Consortium on Current and Future Approaches to Functional Validation for Skeletal Genetic Disease Using Cellular, Molecular and Animal-Modeling Techniques. Frontiers in Endocrinology; 12:731217. doi: 10.3389/fendo.2021.731217. [PubMed]

Bonnet N, Douni E, Perréard Lopreno G, Besse M, Biver E, Ferrari S. (2021). RANKL-Induced Increase in Cathepsin K Levels Restricts Cortical Expansion in a Periostin-Dependent Fashion: A Potential New Mechanism of Bone Fragility. Journal of Bone and Mineral Research; 36(8):1636-1645. doi: 10.1002/jbmr.4307. [PubMed] 

Rinotas V, Papakyriakou A, Violitzi F, Papaneophytou C, Ouzouni MD, Alexiou P, Strongilos A, Couladouros E, Kontopidis G, Eliopoulos E, Douni E. 2020, "Discovery of Small-Molecule Inhibitors of Receptor Activator of Nuclear Factor-κB Ligand with a Superior Therapeutic Index. ", Journal of Medicinal Chemistry, doi: 10.1021/acs.jmedchem.0c01316 [PubMed].

Tratwal J, Labella R, Bravenboer N, Kerckhofs G, Douni E, Scheller EL, Badr S, Karampinos DC, Beck-Cormier S, Palmisano B, Poloni A, Moreno-Aliaga MJ, Fretz J, Rodeheffer MS, Boroumand P, Rosen CJ, Horowitz MC, van der Eerden BCJ, Veldhuis-Vlug AG, Naveiras O. 2020, "Reporting Guidelines, Review of Methodological Standards, and Challenges Toward Harmonization in Bone Marrow Adiposity Research. Report of the Methodologies Working Group of the International Bone Marrow Adiposity Society", Frontiers in Endocrinology, 11:65. doi: 10.3389/fendo.2020.00065 [PubMed].

Bravenboer N, Bredella MA, Chauveau C, Corsi A, Douni E, Ferris WF, Riminucci M, Robey PG, Rojas-Sutterlin S, Rosen C, Schulz TJ, Cawthorn WP. 2020, "Standardised Nomenclature, Abbreviations, and Units for the Study of Bone Marrow Adiposity: Report of the Nomenclature Working Group of the International Bone Marrow Adiposity Society.", Frontiers in Endocrinology, 10:923. doi: 10.3389/fendo.2019.00923 [PubMed].

Violitzi F, Perivolidi VI, Thireou T, Grivas I, Haralambous S, Samiotaki M, Panayotou G, Douni E. 2019, "Mapping Interactome Networks of DNAJC11, a Novel Mitochondrial Protein Causing Neuromuscular Pathology in Mice", Journal of Proteome Research, doi: 10.1021/acs.jproteome.9b00338 [PubMed].

Bonnet N, Bourgoin L, Biver E, Douni E, Ferrari S. 2019, "RANKL inhibition improves muscle strength and insulin sensitivity and restores bone mass", Journal of Clinical Investigation, 129(8):3214-3223. doi: 10.1172/JCI125915 [PubMed].

Papadaki M, Rinotas V, Violitzi F, Thireou T, Panayotou G, Samiotaki M, Douni E. 2019, "New insights for RANKL as a proinflammatory modulator in modeled inflammatory arthritis", Frontiers in Immunology, doi: 10.3389/fimmu.2019.00097 [Link].

Anastasilakis AD, Polyzos SA, Makras P, Douni E, Mantzoros CS. 2019, "Irisin: good or bad for the bone? A new path forward after the reported discovery of irisin receptor?", Metabolism, pii: S0026-0495(19)30028-9. doi: 10.1016/j.metabol.2019.01.013. [PubMed].

Rinotas V, Douni E. 2018, "Molecular Interaction of BMAT with Bone", Current Molecular Biology Reports, 4(2): 34–40 [Link].

Melagraki G, Ntougkos E, Papadopoulou D, Rinotas V, Leonis G, Douni E, Afantitis A, Kollias G. 2018, "In Silico Discovery of Plant-Origin Natural Product Inhibitors of Tumor Necrosis Factor (TNF) and Receptor Activator of NF-κB Ligand (RANKL)", Front Pharmacol, 9: 800 [PubMed].

Plaitakis A, Kotzamani D, Petraki Z, Delidaki M, Rinotas V, Zaganas I, Douni E, Sidiropoulou K, Spanaki C. 2018, "Transgenic Mice Carrying GLUD2 as a Tool for Studying the Expressional and the Functional Adaptation of this Positive Selected Gene in Human Brain Evolution", Neurochem Res., doi: 10.1007/s11064-018-2546-3 [PubMed].

Melagraki G, Leonis G, Ntougkos E, Rinotas V, Papaneophytou C, Mavromoustakos T, Kontopidis G, Douni E, Kolias G, Afantitis A. 2018, "Current Status and Future Prospects of Small–molecule Protein–protein Interaction (PPI) Inhibitors of Tumor Necrosis Factor (TNF) and Receptor Activator of NF-κB Ligand (RANKL)", Curr Top Med Chem, 18(8): 661-673 [PubMed].

Melagraki G, Ntougkos E, Rinotas V, Papaneophytou C, Leonis G, Mavromoustakos T, Kontopidis G, Douni E, Afantitis A, Kollias G. 2017, "Cheminformatics-aided discovery of small-molecule Protein-Protein Interaction (PPI) dual inhibitors of Tumor Necrosis Factor (TNF) and Receptor Activator of NF-κB Ligand (RANKL).", PLoS Comput Biol, 13(4): e1005372 [PubMed].

Terzenidou ME, Segklia A, Kano T, Papastefanaki F, Karakostas A, Charalambous M, Ioakeimidis F, Papadaki M, Kloukina I, Chrysanthou-Piterou M, Samiotaki M, Panayotou G, Matsas R, Douni E. 2017, "Novel insights into SLC25A46-related pathologies in a genetic mouse model", PLoS Genet, Apr 4;13(4): e1006656. doi: 10.1371 [PubMed].

Llop-Guevara A, Porras M, Cendón C, Di Ceglie I, Siracusa F, Madarena F, Rinotas V, Gómez L, van Lent PL, Douni E, Chang HD, Kamradt T, Román J. 2015, "Simultaneous inhibition of JAK and SYK kinases ameliorates chronic and destructive arthritis in mice", Arthritis Res Ther, 17:356. [PubMed].

Papaneophytou C, Alexiou P, Papakyriakou A, Ntougkos E, Tsiliouka K, Maranti A, Liepouri F, Strongilos A, Mettou A, Couladouros E, Eliopoulos E, Douni E, Kollias G, Kontopidis G. 2015, "Synthesis and biological evaluation of potential small molecule inhibitors of tumor necrosis factor", Med. Chem. Commun, 6 : 1196-1209. [PubMed].

Agas D, Marchetti L, Douni E, Sabbieti MG. 2015, "The unbearable lightness of bone marrow homeostasis", Cytokine & Growth Factor Reviews, 26(3) :347-59 [PubMed].

Alexiou P, Papakyriakou A, Ntougkos E, Papaneophytou CP, Liepouri F, Mettou A, Katsoulis I, Maranti A, Tsiliouka K, Strongilos A, Chaitidou S, Douni E, Kontopidis G, Kollias G, Couladouros E, Eliopoulos E. 2014, "Rationally designed less toxic SPD-304 analogs and preliminary evaluation of their TNF inhibitory effects", Arch Pharm, 347(11): 798-805 [PubMed].

Ioakeimidis F, Ott C, Kozjak-Pavlovic V, Violitzi F, Rinotas V, Makrinou E, Eliopoulos E, Fasseas C Kollias G, Douni E. 2014, "A splicing mutation in the novel mitochondrial protein DNAJC11 causes motor neuron pathology associated with cristae disorganization, and lymphoid abnormalities in mice", PLoS One, 9(8) :e104237 [PubMed].

Perperopoulou FD, Tsoungas PG, Thireou TN, Rinotas VE, Douni EK, Eliopoulos EE, Labrou NE, Clonis YD. 2014, "2,2'-Dihydroxybenzophenones and their carbonyl N-analogues as inhibitor scaffolds for MDR-involved human glutathione transferase isoenzyme A1-1", Bioorganic and Medicinal Chemistry, 22(15) :3957-70 [PubMed].

Rinotas V, Niti A, Dacquin R, Bonnet N, Stolina M, Han CY, Kostenuik P, Jurdic P, Ferrari S, Douni E. 2014, "Novel genetic models of osteoporosis by overexpression of human RANKL in transgenic mice", J Bone Miner Res. , 29(5) :1158-69 [PubMed].

Zoi OG, Thireou TN, Rinotas VE, Tsoungas PG, Eliopoulos EE Douni EK, Labrou NE, Clonis YD 2013, "Designer Xanthone: An Inhibitor Scaffold for MDR-Involved Human Glutathione Transferase Isoenzyme A1-1", J Biomol Screen, , 2013 Oct; 18(9):1092-102. [PubMed].

Papaneophytou CP, Rinotas V, Douni E, Kontopidis G. 2013, "A statistical approach for optimization of RANKL overexpression in Escherichia coli: Purification and characterization of the protein", Protein Expr Purif, , 2013 Jul; 90(1):9-19 [PubMed].

Bonaparte D, Cinelli P, Douni E, Hérault Y, Maas A, Pakarinen P, Poutanen M, Lafuente MS, Scavizzi F 2013, "FELASA guidelines for the refinement of methods for genotyping genetically-modified rodents: a report of the Federation of European Laboratory Animal Science Associations Working Group", Lab Anim, , 2013 Jul; 47(3):134-45. [PubMed].

Papaneophytou CP, Mettou AK, Rinotas V, Douni E, Kondopidis GA. 2013, "Solvent Selection for Insoluble Ligands, a Challenge for Biological Assay Development: A TNF-α/SPD304 Study", ACS Med. Chem. Lett; , 4 (1):137–141. [PubMed].

Douni E, Rinotas V, Makrinou E, Zwerina J, Penninger JM, Eliopoulos E, Schett G, Kollias G. 2012, "A RANKL G278R mutation causing osteopetrosis identifies a functional amino acid essential for trimer assembly in RANKL and TNF.", Hum Mol Genet. , 2012 Feb 15. 21(4):784-98. [PubMed].

Morgan H, Beck T, Blake A, Gates H, Adams N, Debouzy G, Leblanc S, Lengger C, Maier H, Melvin D, Meziane H, Richardson D, Wells S, White J, Wood J, EUMODIC Consortium , de Angelis MH, Brown SD, Hancock JM, Mallon AM., 2010, "EuroPhenome: a repository for high-throughput mouse phenotyping data.", Nucleic Acids Res, 2010 Jan;38(Database issue):, D577-85. Epub 2009 Nov 23.; [PubMed].

Thwin MM, Douni E, Arjunan P, Kollias G, Kumar PV, Gopalakrishnakone P. 2009, "Suppressive effect of secretory phospholipase A2 inhibitory peptide on interleukin-1beta-induced matrix metalloproteinase production in rheumatoid synovial fibroblasts, and its antiarthritic activity in hTNFtg mice.", Arthritis Res Ther., 2009 Sep 18;11(5):R138. [Epub ahead of print] , [PubMed]

Douni E,Armaka M, Kontoyiannis DL, Kollias G 2007, "Functional genetic and genomic analysis of modeled arthritis.", Adv Exp Med Biol. , 2007; , 602:33-42 [PubMed].

Aidinis V, Chandras C, Manoloukos M, Thanassopoulou A, Kranidioti K, Armaka M Douni E, Kontoyiannis DL, Zouberakis M, Kollias G; Mugen NoE consortium 2007, "MUGEN mouse database; animal models of human immunological diseases.", Nucleic Acids Res. , 2008 Jan;36(Database issue) , D1048-54. Epub 2007 Oct 11. [PubMed].

Alexopoulou L, Kranidioti K, Xanthoulea S, Denis M, Kotanidou A Douni E, Blackshear PJ, Kontoyiannis DL, Kollias G. 2006, "Transmembrane TNF protects mutant mice against intracellular bacterial infections, chronic inflammation and autoimmunity.", Eur J Immunol. , 2006 Oct;36(10) , 2768-80. [PubMed].

Thwin MM, Douni E, Aidinis V, Kollias G, Kodama K, Sato K, Satish RL, Mahendran R, Gopalakrishnakone P. 2004, "Effect of phospholipase A2 inhibitory peptide on inflammatory arthritis in a TNF transgenic mouse model: a time-course ultrastructural study.", Arthritis Res Ther. , 2004;6(3) , R282-94. Epub 2004 Apr 28 [PubMed].

Douni E, Alexiou M, Kollias G. 2004, "Genetic engineering in the mouse: tuning TNF/TNFR expression.", Methods Mol Med. , 2004;98: , 137-70 [PubMed].

Douni E, Sfikakis PP, Haralambous S, Fernandes P, Kollias G. 2004, "Attenuation of inflammatory polyarthritis in TNF transgenic mice by diacerein: comparative analysis with dexamethasone, methotrexate and anti-TNF protocols.", Arthritis Res Ther. , 2004;6(1) , :R65-R72. Epub 2003 Nov 7. [PubMed].

Holtmann MH, Douni E, Schütz M, Zeller G, Mudter J, Lehr HA, Gerspach J, Scheurich P, Galle PR, Kollias G, Neurath MF. 2002, "Tumor necrosis factor-receptor 2 is up-regulated on lamina propria T cells in Crohn's disease and promotes experimental colitis in vivo.", Eur J Immunol. , 2002 Nov;32(11) , :3142-51 [PubMed].

Akassoglou K, Douni E, Bauer J, Lassmann H, Kollias G, Probert L. 2003, "Exclusive tumor necrosis factor (TNF) signaling by the p75TNF receptor triggers inflammatory ischemia in the CNS of transgenic mice.", Proc Natl Acad Sci U S A. , 2003 Jan 21;100(2), :709-14. Epub 2003 Jan 9. [PubMed].

Kollias G, Kontoyiannis D, Douni E, Kassiotis G. 2002, "The role of TNF/TNFR in organ-specific and systemic autoimmunity: implications for the design of optimized 'anti-TNF' therapies.", Curr Dir Autoimmun. , 2002;5: , 30-50 [PubMed].

Kollias G, Douni E, Kassiotis G, Kontoyiannis D. 1999, "The function of tumour necrosis factor and receptors in models of multi-organ inflammation, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease.", Ann Rheum Dis , 1999 Nov; , 58 Suppl 1:I32-9 [PubMed].

Kollias G, Douni E, Kassiotis G, Kontoyiannis D. 1999, "On the role of tumor necrosis factor and receptors in models of multiorgan failure, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease.", Immunol Rev. , 1999 Jun; , 169:175-94 [PubMed].

Douni E, Kollias G. 1998, "A critical role of the p75 tumor necrosis factor receptor (p75TNF-R) in organ inflammation independent of TNF, lymphotoxin alpha, or the p55TNF-R.", J Exp Med. , 1998 Oct 5; , 188(7):1343-52. [PubMed].

Küsters S, Tiegs G, Alexopoulou L, Pasparakis M, Douni E, Künstle G, Bluethmann H, Wendel A, Pfizenmaier K, Kollias G, Grell M. 1997, "In vivo evidence for a functional role of both tumor necrosis factor (TNF) receptors and transmembrane TNF in experimental hepatitis.", Eur J Immunol.; , 1997 Nov , 27(11):2870-5. [PubMed].

Pasparakis M, Alexopoulou L, Douni E, Kollias G. 1996, "Tumour necrosis factors in immune regulation: everything that's interesting is...new!", Cytokine Growth Factor Rev. ; , 1996 Oct , 7(3):223-9. [PubMed].

Probert L, Akassoglou K, Alexopoulou L, Douni E, Haralambous S, Hill S, Kassiotis G, Kontoyiannis D, Pasparakis M, Plows D, Kollias G. 1996, "Dissection of the pathologies induced by transmembrane and wild-type tumor necrosis factor in transgenic mice.", J Leukoc Biol. , 1996 Apr; , 59(4):518-25 [PubMed].

Grell M, Douni E, Wajant H, Löhden M, Clauss M, Maxeiner B, Georgopoulos S, Lesslauer W, Kollias G, Pfizenmaier K, Scheurich P. 1995, "The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor.", Cell , 1995 Dec 1;, 83(5):793-802 [PubMed].

Douni E, Akassoglou K, Alexopoulou L, Georgopoulos S, Haralambous S, Hill S, Kassiotis G, Kontoyiannis D, Pasparakis M, Plows D, Probert L, Kollias G. 1995, "Transgenic and knockout analyses of the role of TNF in immune regulation and disease pathogenesis.", J Inflamm. , 1995-1996; , 47(1-2):27-38 [PubMed].